BiotechTube

zigakibart

Phase 2Recruiting
0 views this week 0 watching⚡ Active
Interest: 42/100
42
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Immunoglobulin A Nephropathy (IgAN)

Conditions

Immunoglobulin A Nephropathy (IgAN)

Trial Timeline

Feb 20, 2026 → Oct 18, 2030

NCT ID
NCT07146906

About zigakibart

zigakibart is a phase 2 stage product being developed by Novartis for Immunoglobulin A Nephropathy (IgAN). The current trial status is recruiting. This product is registered under clinical trial identifier NCT07146906. Target conditions include Immunoglobulin A Nephropathy (IgAN).

What happened to similar drugs?

0 of 4 similar drugs in Immunoglobulin A Nephropathy (IgAN) were approved

Approved (0) Terminated (0) Active (4)
🔄iptacopanNovartisPhase 3
🔄Rilzabrutinib + Placebo + GlucocorticoidSanofiPhase 3
🔄Felzartamab + PlaceboBiogenPhase 3
🔄sparsentan + irbesartan + DapagliflozinTravere TherapeuticsPhase 3

Hype Score Breakdown

Clinical
12
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT07146906Phase 2Recruiting
NCT06858319Phase 3Recruiting

Competing Products

11 competing products in Immunoglobulin A Nephropathy (IgAN)

See all competitors
ProductCompanyStageHype Score
ABBV-383 (Etentamig)AbbViePhase 1/2
39
iptacopanNovartisPhase 3
47
CCX168AmgenPhase 2
35
InebilizumabAmgenPhase 2
42
Rilzabrutinib + Placebo + GlucocorticoidSanofiPhase 3
47
rilzabrutinib + GlucocorticoidsSanofiPhase 2
35
FelzartamabBiogenPhase 2
32
Felzartamab + PlaceboBiogenPhase 3
44
SparsentanTravere TherapeuticsPhase 2
29
SparsentanTravere TherapeuticsPhase 2
33
sparsentan + irbesartan + DapagliflozinTravere TherapeuticsPhase 3
38